Generative AI is revolutionizing Drug-Target Interaction (DTI) prediction by automating drug design, improving binding accuracy, and accelerating discovery timelines. It replaces manual, trial-and-error methods with predictive, end-to-end pipelines. While challenges like interpretability and data quality persist, real-world case studies show its promise. GenAI is set to reshape pharma by making drug discovery faster, smarter, and more scalable.

Generative AI is transforming drug optimization by accelerating analog design, improving ADMET predictions, and automating synthesis planning. Traditionally taking 12–24 months, this phase can now be shortened by up to 50%, with cost savings of 30–40%. From analog generation to compound prioritization, Gen AI enables faster, smarter decisions—empowering teams and reshaping the future of drug development.

The Gen AI in Manufacturing Report 2025 by Pitchworks is a definitive industry blueprint, unlocking the power of generative AI to transform modern manufacturing. Authored by veteran technologist Murali Sundaram and backed by Pitchworks VC Studio’s $8M innovation commitment, this 80+ page report presents a bold, research-backed roadmap for deploying generative AI across product design, predictive maintenance, supply chain optimization, quality control, and autonomous systems.

Many enterprises struggle with GenAI adoption due to vague use cases, weak leadership support, and poor change management. Pitchworks VC Studio offers a 9-stage GenAI Strategy Roadmap designed to solve this—starting from leadership alignment and AI training to use case mapping, implementation, and continuous upskilling. This framework ensures enterprises unlock ROI-driven, scalable, and sustainable AI impact across functions.